Social Impact Capital — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Curemarkcuremark.comMar 2017SEC filingmedium confidence
Curemark is a clinical-stage biopharmaceutical company developing therapies for neuro-developmental and neurodegenerative disorders.
BiotechHealthtechRye Brook, US
Joan Fallon(Executive Officer, Director)Matthew Heil(Executive Officer)Kimball Duncan(Manager of the LLC)Klaus Kleinfeld(Manager of the LLC)Eric Herman(Manager of the LLC)
BoardLeigh Morgan(Director)
Board seatJustin Stebbing· per SEC Form D · $150M raise · filed Mar 2017
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.